What are the differences in transmissibility between novel and emerging SARS-CoV-2 variants? medrxivpreprint LSHTM Transmissibility COVID19 SARSCoV2 Variants
By Bhavana KunkalikarSep 29 2022Reviewed by Aimee Molineux In a recent study posted to the medRxiv* preprint server, researchers compared the transmissibility of novel and emerging severe acute respiratory syndrome coronavirus 2 variants.
About the study In the present study, researchers determined the frequencies of household secondary attacks using serology to assess the relative transmissibility of the SARS-CoV-2 Alpha variant of concern to non-VOC SARS-CoV-2. For the first hospital index cases, the team started hiring on 26 March 2021, and for the second hospital, the hiring started on 11 May 2021. The hiring process was finished by 11 July 2021.
SARS-CoV-2 diagnosis simultaneous to the index cases was reported by 47% of contacts exposed to non-VOC-infected index and 67% of those exposed to Alpha-infected index cases. Not all contacts diagnosed with COVID-19 were experiencing symptoms at the time. Nonetheless, contacts of an Alpha index case reported COVID-19 symptoms or a SARS-CoV-2 diagnosis more frequently and had higher anti-nucleocapsid IgG titers.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Study aims to understand how SARS-CoV-2 affects the brain long-termResearchers formulate a method to identify the molecular and systemic factors linking COVID-19 to short- and long-term neurologic illness.
Consulte Mais informação »
Q-LAAD: a dynamic, cost-effective rapid antigen test for detection of SARS-CoV-2Researchers developed a high-throughput, rapid antigen SARS-CoV-2 spike protein detection test using allonamers, a new type of aptamers that carry out allosteric regulation instead of catalytic activity.
Consulte Mais informação »
Food, vaccines, bacteria, and viruses may all prime our immune system to attack SARS-CoV-2Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, primarily causes mild to moderate upper-respiratory tract illness. However, some individuals with COVID-19 develop severe infections and require hospital admission.
Consulte Mais informação »
Observing SARS-CoV-2 Omicron reinfections with different sub-variantsObserving SARS-CoV-2 Omicron reinfections with different sub-variants SARSCoV2 COVID19 Omicron Reinfection CDCgov
Consulte Mais informação »
COVID-19 cases, hospitalizations, and fatalities prevented by SARS-CoV-2 vaccination within the first 6 months after the vaccine became availableCOVID-19 cases, hospitalizations, and fatalities prevented by SARS-CoV-2 vaccination within the first 6 months after the vaccine became available medrxivpreprint Columbia ColumbiaMSPH COVID19 coronavirus covid vaccination vaccine SARSCoV2
Consulte Mais informação »
What is the role of N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 spike maturation?A new study showed that SARS-CoV-2 Spike N-glycosylation patterns, intracellular lectins, and the associated molecular chaperones play crucial roles in the viral-host-cell invasion and function.
Consulte Mais informação »